Genomic Health, Inc.Yuko Soneoka, Ph.D., J.D.

Senior Corporate Counsel, IP

Director of Intellectual Property

January 31, 2013

What We Do

• Genomic Health is a global personalized genomics health company focusing on cancer

• Conduct studies to understand which patterns of gene expression within a tumor are linked to a response to cancer therapy or to the likelihood that the cancer will return or metastasize

• Develop clinically validated tests that provide the genomic profile of an individual’s tumor in the form of a “score” that helps individualize cancer treatment planning

2

Leading a Revolution in Cancer Care

3 * Estimated

DCISBreast Cancer

Stage II/ MMRColon Cancer

ProstateCancer

Do I have anDo I have an aggressive aggressive disease? disease?

Do I needDo I need surgery?surgery?

Stage II/IIIColon Cancer

Do I needDo I needOxaliplatin?Oxaliplatin?

InvasiveBreast Cancer

Do I needDo I needchemotherapy?chemotherapy?

Do I needDo I needradiation?radiation?

2005 2006 2007 2008 2009 2010 2011 2012 2013* 2014*

NGS Research NGS Development

DCIS Breast Cancer Assay

4

“One of the year’s leading medical breakthroughs…”

DCIS Score DCIS Score Identifies Identifies 75% of Patients75% of Patients with with Lower Risk Disease Lower Risk Disease

Who May Avoid Who May Avoid Radiation TreatmentRadiation Treatment

DCIS Score DCIS Score Identifies Identifies 75% of Patients75% of Patients with with Lower Risk Disease Lower Risk Disease

Who May Avoid Who May Avoid Radiation TreatmentRadiation Treatment

Delivering Better Outcomes in Cancer

Cancer’s Toll in 2012•1.6 million new cancers will be diagnosed in the U.S.1

•~577,000 patients will die from their disease1

•80 billion dollars will be spent on cancer therapies with an average efficacy of 25%2

•60 billion dollars will be wasted

In Early Stage ER+ Invasive Breast Cancer•>100,000 patients will be diagnosed in the U.S.•>50% percent will receive chemotherapy3

•<4% of N- patients will benefit from chemotherapy

The Oncotype DX® Value Proposition•Demonstrated 37% change in early-stage breast cancer treatment decisions•Hundreds of millions of dollars in healthcare savings•>320,000 patients tested

5 1 ACS 2012; 2 Burrill 2009; 3 Company estimates

Thank You

6